Dermal Relief

CLINICAL STUDIES ON THE FOLLOWING INGREDIENTS:

L-histidine

Feeding filaggrin: effects of l-histidine supplementation in atopic dermatitis

Abstract

Atopic dermatitis (AD), also known as eczema, is one of the most common chronic skin conditions worldwide, affecting up to 16% of children and 10% of adults. It is incurable and has significant psychosocial and economic impacts on the affected individuals. AD etiology has been linked to deficiencies in the skin barrier protein, filaggrin. In mammalian skin, l-histidine is rapidly incorporated into filaggrin. Subsequent filaggrin proteolysis releases l-histidine as an important natural moisturizing factor (NMF). In vitro studies were conducted to investigate the influence of l-histidine on filaggrin processing and barrier function in human skin-equivalent models. Our further aim was to examine the effects of daily oral l-histidine supplementation on disease severity in adult AD patients. We conducted a randomized, double-blind, placebo-controlled, crossover, nutritional supplementation pilot study to explore the effects of oral l-histidine in adult AD patients (n=24). In vitro studies demonstrated that l-histidine significantly increased both filaggrin formation and skin barrier function (P < 0.01, respectively). Data from the clinical study indicated that once daily oral l-histidine significantly reduced (P < 0.003) AD disease severity by 34% (physician assessment using the SCORingAD tool) and 39% (patient self-assessment using the Patient Oriented Eczema Measure tool) after 4 weeks of treatment. No improvement was noted with the placebo (P>0.32). The clinical effect of oral l-histidine in AD was similar to that of mid-potency topical corticosteroids and combined with its safety profile suggests that it may be a safe, nonsteroidal approach suitable for long-term use in skin conditions that are associated with filaggrin deficits such as AD.

Source: Siao Pei Tan, Simon B Brown, Christopher EM Griffiths, Richard B Weller and Neil K Gibbs “Feeding filaggrin: effects of l-histidine supplementation in atopic dermatitis” Clin Cosmet Investig Dermatol. 2017; 10: 403–411.

L-Histidine Supplementation in Adults and Young Children with Atopic Dermatitis (Eczema)

Abstract

Atopic dermatitis (AD) is an incurable, inflammatory skin condition that is prevalent (∼20%) in young children. There is an unmet clinical need, particularly in children, for safe interventions that target the etiology of the disease. Deficiencies in the skin barrier protein, filaggrin (FLG) have been identified as major predisposing factors in AD. In mammals, L-histidine is rapidly incorporated into epidermal FLG and subsequent FLG proteolysis releases L-histidine as an important natural moisturizing factor (NMF). It has therefore been hypothesized that L-histidine supplementation would be a safe approach to augment both FLG and the NMF, enhance skin barrier function, and reduce AD severity. In a clinical pilot study, adult subjects (n = 24) with AD took either a placebo or 4 g oral L-histidine daily for 8 wk. Unlike the placebo, L-histidine reduced AD (34% reduction in SCORing Atopic Dermatitis scores; P < 0.003) after 4 wk. Nine and 8 adverse events (AEs), and 1 and 0 severe AEs were recorded in the L-histidine or placebo groups, respectively, with no AE being causally related to L-histidine ingestion. A survey of adults (n = 98) taking 4 g L-histidine daily reiterated a lack of causal AEs and also reported a 33% reduction in topical corticosteroid use. A placebo-controlled, clinical pilot study conducted in young children with AD (n = 49; mean age 3.5 y) taking 0.8 g L-histidine daily, showed that eczema area and severity index scores were reduced by 49% (P < 0.02) at 12 wk, whereas a placebo had no effect. The children taking L-histidine had 50 minor AEs (compared with 39 on placebo), with 78% considered as “not,” 18% “unlikely,” and 4% “possibly” related to L-histidine ingestion. These studies indicate that at the levels reported, oral L-histidine supplementation is well tolerated and has potential as a safe intervention for long-term use in the management of AD in all age groups.

Source: Neil K Gibbs “L-Histidine Supplementation in Adults and Young Children with Atopic Dermatitis (Eczema) ”The Journal of Nutrition, Volume 150, Issue Supplement_1, October 2020, Pages 2576S–2579S.

Results of Histidine (His) Supplementation in a Case of Severe Nummular Eczema (NE)

Abstract

NE (coin-shaped, severely pruritic skin lesions) is an idiopathic, histologically indistinguishable form of atopic dermatitis (AD). NE is chronic, relapsing and debilitating. Treatment is limited to skin moisturizers and anti-inflammatory agents. Recurrence is common. Recent studies suggest that lack of the protein, filaggrin (FLG) and its derivative natural moisturizing factors (NMFs) play a role. Because FLG is a His-rich compound, l-His supplementation (LHS) may provide a nutritional NE option. In this report, we present a patient with severe, resistant NE who responded to LHS. The patient is a 57 yo female with NE, unresponsive to topical emollients, topical and oral steroids, oral antihistamines, phototherapy, topical calcineurin inhibitors and immune modulating agents. She attempted nutritional options by eliminating food allergens (dairy, nuts, wheat, eggs) and followed an anti-inflammatory diet. Because these had only modest effects, a trial of oral LHS (8 gm/d) was begun. After 4 months on therapy NE improved significantly. Lesions diminished in size and number. The pruritus was nearly eliminated. Liver and kidney function remained normal.

Source: Michael Rothkopf “Results of Histidine (His) Supplementation in a Case of Severe Nummular Eczema (NE)” Curr Dev Nutr. 2020 Jun; 4(Suppl 2): 1141.

Dermal Relief

CLINICAL STUDIES ON THE FOLLOWING INGREDIENTS:

L-histidine

Feeding filaggrin: effects of l-histidine supplementation in atopic dermatitis

Abstract

L-Histidine Supplementation in Adults and Young Children with Atopic Dermatitis (Eczema)

Abstract

Results of Histidine (His) Supplementation in a Case of Severe Nummular Eczema (NE)

Abstract

References: